TD Asset Management Inc Buys 95,548 Shares of Immatics N.V. $IMTX

TD Asset Management Inc increased its stake in Immatics N.V. (NASDAQ:IMTX) by 33.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 383,804 shares of the company’s stock after buying an additional 95,548 shares during the period. TD Asset Management Inc owned 0.32% of Immatics worth $3,270,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Bank of America Corp DE increased its holdings in shares of Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares in the last quarter. Fox Run Management L.L.C. purchased a new stake in Immatics during the 2nd quarter valued at about $136,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Immatics by 28.7% during the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 31,894 shares of the company’s stock valued at $172,000 after purchasing an additional 7,116 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Immatics by 31.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock valued at $1,069,000 after purchasing an additional 47,590 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in Immatics by 105.2% in the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock worth $420,000 after buying an additional 40,058 shares during the last quarter. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Stock Up 3.5%

NASDAQ IMTX opened at $10.18 on Thursday. The company has a 50-day moving average price of $9.90 and a 200-day moving average price of $9.13. Immatics N.V. has a 52 week low of $3.30 and a 52 week high of $12.41. The firm has a market capitalization of $1.24 billion, a P/E ratio of -9.98 and a beta of 1.34.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on IMTX. Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of Immatics in a report on Monday, November 24th. Wall Street Zen lowered Immatics from a “hold” rating to a “sell” rating in a report on Sunday. Mizuho set a $25.00 price target on Immatics in a research note on Thursday, February 19th. Guggenheim increased their price objective on Immatics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immatics presently has a consensus rating of “Moderate Buy” and an average target price of $19.20.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.